Pfizer says clotting drug's once-weekly dose reduces bleeding rate
July 16 (Reuters) - Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.
Hemophilia B patients taking the drug, BeneFIX, once a week showed a statistically significant reduction in the annualized bleeding rate compared with those administered the drug on demand. (Reporting by Shailesh Kuber in Bangalore; Editing by Kirti Pandey)
- British Muslims blame jihadi subculture after beheading video |
- Israeli air strike kills three Hamas commanders in Gaza |
- U.S. aid workers released from Atlanta hospital after cleared of Ebola |
- Obama condemns killing of reporter, U.S. hits militants in Iraq |
- Ukraine border guards begin checks on Russian aid trucks